Fungal vaccines and immunotherapeutics

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 11, 2014, Pages

  Santos, Evelyn ^a   Levitz, Stuart M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ANTIBODY; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; DENDRITIC CELL VACCINE; DIPHTHERIA TOXIN; FUNGUS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; LAMINARAN; LIVE VACCINE; MONOCLONAL ANTIBODY; POLYSACCHARIDE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TETANUS TOXIN; VACCINE; RECOMBINANT VACCINE;

ADAPTIVE IMMUNITY; ANTIFUNGAL ACTIVITY; ANTIGEN PRESENTING CELL; ARTICLE; CANDIDA; CLINICAL TRIAL (TOPIC); COCCIDIOIDOMYCOSIS; DENDRITIC CELL; DRUG EFFICACY; FUNGAL STRAIN; FUNGUS; FUNGUS IMMUNITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION PREVENTION; INFLAMMATION; INNATE IMMUNITY; INVASIVE CANDIDIASIS; LEUKOCYTE; MORTALITY; MYCOSIS; NONHUMAN; PASSIVE IMMUNIZATION; REGULATORY T LYMPHOCYTE; IMMUNOLOGY; MYCOSES; PROCEDURES;

FUNGAL VACCINES; HUMANS; IMMUNOTHERAPY; MYCOSES; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 84923884965     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a019711     Document Type: Article

References (75)

1. ACIP. 2011. General recommendations on immunization—Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60: 1-64.
2. Armstrong-James D, Harrison TS. 2012. Immunotherapy for fungal infections. Curr Opin Microbiol 15: 434-439.
3. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. 2007. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun 75: 1424-1435.
4. Bozza S, Clavaud C, Giovannini G, Fontaine T, Beauvais A, Sarfati J, D’Angelo C, Perruccio K, Bonifazi P, Zagarella S, et al. 2009. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 183: 2407-2414.
5. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: Human fungal infections. Sci Transl Med 4: 165-113.
6. Bruhns P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
7. Bryan RA, Jiang A, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. 2010. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis 202: 633-637.
8. Capilla J, Clemons KV, Liu M, Levine HB, Stevens DA. 2009. Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 27: 3662-3668.
9. Capodicasa C, Chiani P, Bromuro C, De Bernardis F, Catellani M, Palma AS, Liu Y, Feizi T, Cassone A, Benvenuto E, et al. 2011. Plant production of anti-b-glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotechnol J 9: 776-787.
10. Carvalho A, Cunha C, Bozza S, Moretti S, Massi-Benedetti C, Bistoni F, Aversa F, Romani L. 2012. Immunity and tolerance to fungi in hematopoietic transplantation: Principles and perspectives. Front Immunol 3: 156.
11. Cassone A. 2008. Fungal vaccines: Real progress from real challenges. Lancet Infect Dis 8: 114-124.
12. Cassone A, De Bernardis F, Santoni G. 2007. Anticandidal immunity and vaginitis: Novel opportunities for immune intervention. Infect Immun 75: 4675-4686.
13. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. 2006. Hospitalizations for endemic mycoses: A populationbased national study. Clin Infect Dis 42: 822-825.
14. Cutler JE, Deepe GS Jr, Klein BS. 2007. Advances in combating fungal diseases: Vaccines on the threshold. Nat Rev Microbiol 5: 13-28.
15. Dadachova E, Nakouzi A, Bryan RA, Casadevall A. 2003. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci 100: 10942-10947.
16. Dan JM, Levitz SM. 2006. Prospects for development of vaccines against fungal diseases. Drug Resist Updat 9: 105-110.
17. De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, Moser C, Cassone A. 2012. Avirosomal vaccine against candidal vaginitis: Immunogenicity, efficacy and safety profile in animal models. Vaccine 30: 4490-4498.
18. Devi SJ. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14: 841-844.
19. Dimopoulos G, Antonopoulou A, Armaganidis A, Vincent JL. 2013. How to select an antifungal agent in critically ill patients. J Crit Care 28: 717-727.
20. Dwivedi P, Thompson A, Xie Z, Kashleva H, Ganguly S, Mitchell AP, Dongari-Bagtzoglou A. 2011. Role of Bcr1-activated genes Hwp1 and Hyr1 in Candida albicans oral mucosal biofilms and neutrophil evasion. PLoS ONE 6: e16218.
21. Guimaraes AJ, Frases S, Gomez FJ, Zancope-Oliveira RM, Nosanchuk JD. 2009. Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun 77: 1357-1367.
22. Hamad M. 2008. Antifungal immunotherapy and immunomodulation: A double-hitter approach to deal with invasive fungal infections. Scand J Immunol 67: 533-543.
23. Hardison SE, Brown GD. 2012. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol 13: 817-822.
24. Hogan LH, Klein BS, Levitz SM. 1996. Virulence factors of medically important fungi. Clin Microbiol Rev 9: 469-488.
25. Hole CR, Wormley FL Jr. 2012. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: Lessons learned from animal models. Front Microbiol 3: 291.
26. Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, Rice PA, Specht CA, Levitz SM. 2012. Relative contributions of dectin-1 and complement to immune responses to particulate b-glucans. J Immunol 189: 312-317.
27. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. 2013. Characterization and optimization of the glucan particlebased vaccine platform. Clin Vaccine Immunol 20: 1585-1591.
28. Iannitti RG, Carvalho A, Romani L. 2012. From memory to antifungal vaccine design. Trends Immunol 33: 467-474.
29. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JP Jr, French SW, Yeaman MR, Filler SG, Edwards JE Jr. 2013. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 31: 5549-5556.
30. Kehry MR, Castle BE. 1994. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin Immunol 6: 287-294.
31. Kehry MR, Hodgkin PD. 1993. Helper T cells: Delivery of cell contact and lymphokine-dependent signals to B cells. Semin Immunol 5: 393-400.
32. Lam JS, Mansour MK, Specht CA, Levitz SM. 2005. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 175: 7496-7503.
33. Latge JP. 2010. Tasting the fungal cell wall. Cell Microbiol 12: 863-872.
34. Levine MM, Sztein MB. 2004. Vaccine development strategies for improving immunization: The role of modern immunology. Nat Immunol 5: 460-464.
35. Levitz SM, Golenbock DT. 2012. Beyond empiricism: Informing vaccine development through innate immunity research. Cell 148: 1284-1292.
36. Levitz SM, Specht CA. 2006. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res 6: 513-524.
37. Liu M, Capilla J, Johansen ME, Alvarado D, Martinez M, Chen V, Clemons KV, Stevens DA. 2011a. Saccharomyces as a vaccine against systemic aspergillosis: “The friend of man” a friend again? J Med Microbiol 60: 1423-1432.
38. Liu M, Clemons KV, Bigos M, Medovarska I, Brummer E, Stevens DA. 2011b. Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection. Vaccine 29: 1745-1753.
39. Liu M, Clemons KV, Johansen ME, Martinez M, Chen V, Stevens DA. 2012a. Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest 41: 847-855.
40. Liu M, Machova E, Nescakova Z, Medovarska I, Clemons KV, Martinez M, Chen V, Bystricky S, Stevens DA. 2012b. Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol 50: 818-828.
41. Lopes LC, Guimaraes AJ, de Cerqueira MD, Gomez BL, Nosanchuk JD. 2010. A Histoplasma capsulatum-specific IgG1 isotype monoclonal antibody, H1C, to a 70-kilodalton cell surface protein is not protective in murine histoplasmosis. Clin Vaccine Immunol 17: 1155-1158.
42. Magalhaes A, Ferreira KS, Almeida SR, Nosanchuk JD, Travassos LR, Taborda CP. 2012. Prophylactic and therapeutic vaccination using dendritic cells primed with peptide 10 derived from the 43-kilodalton glycoprotein of Paracoccidioides brasiliensis. Clin Vaccine Immunol 19: 23-29.
43. Mestas J, Hughes CC. 2004. Of mice and not men: Differences between mouse and human immunology. J Immunol 172: 2731-2738.
44. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. 1995. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 181: 405-409.
45. Murphy K, Travers P, Walport M, Janeway C. 2012a. Janeway’s immunobiology, p. 354. Garland, New York.
46. Murphy K, Travers P, Walport M, Janeway C. 2012b. Janeway’s immunobiology, p. 402. Garland, New York.
47. NIH. 2010. A phase I clinical trial for recurrent vulvovaginal candidiasis. Identification No. NCT01067131, National Institutes of Health, Bethesda, MD, clinicaltrials.gov.
48. Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185: 685-694.
49. Pappagianis D. 1993. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 148: 656-660.
50. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
51. Perlroth J, Choi B, Spellberg B. 2007. Nosocomial fungal infections: Epidemiology, diagnosis, and treatment. Med Mycol 45: 321-346.
52. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
53. Phan QT, Myers CL, Fu Y, Sheppard CD, Yeaman MR, Welch WH, Ibrahim AS, Edwards JE Jr, Filler SG. 2007. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 5: e64.
54. Pirofski LA, Casadevall A. 1998. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 11: 1-26.
55. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797.
56. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G, Velardi A, et al. 2006. Thymosin a1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.
57. Roush SW, Murphy TV. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298: 2155-2163.
58. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE Jr, Hennessey JP Jr. 2012. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 30: 7594-7600.
59. Schroeder HW Jr, Cavacini L. 2010. Structure and function of immunoglobulins. J Allergy Clin Immunol 125: S41-S52.
60. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. 2007. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 196: 796-800.
61. Spellberg BJ, Ibrahim AS, Avanesian V, Fu F, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr. 2006. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194: 256-260.
62. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, et al. 2008. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 76: 4574-4580.
63. Steinman RM, Banchereau J. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
64. Taborda CP, Juliano MA, Puccia R, Franco M, Travassos LR. 1998. Mapping of the T-cell epitope in the major 43-kilodalton glycoprotein of Paracoccidioides brasiliensis which induces a Th-1 response protective against fungal infection in BALB/c mice. Infect Immun 66: 786-793.
65. Toews GB. 2001. Cytokines and the lung. Eur Respir J Suppl 34: 3s-17s.
66. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, et al. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202: 597-606.
67. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, et al. 2009. Protection by anti-b-glucan antibodies is associated with restricted b-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4: e5392.
68. Tritto E, Mosca F, De Gregorio E. 2009.Mechanism of action of licensed vaccine adjuvants. Vaccine 27: 3331-3334.
69. Vecchiarelli A, Pericolini E, Gabrielli E, Pietrella D. 2012. New approaches in the development of a vaccine for mucosal candidiasis: Progress and challenges. Front Microbiol 3: 294.
70. Wormley FL Jr, Perfect JR, Steele C, Cox GM. 2007. Protection against cryptococcosis by using a murine g interferon-producing Cryptococcus neoformans strain. Infect Immun 75: 1453-1462.
71. Wozniak KL, Young ML, Wormley FL Jr. 2011. Protective immunity against experimental pulmonary cryptococcosis in T-cell-depleted mice. Clin Vaccine Immunol 18: 717-723.
72. Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr, Klein BS. 2003. Vaccine immunity to pathogenic fungi over-comes the requirement for CD4 help in exogenous antigen presentation to CD8þ T cells: Implications for vaccine development in immune-deficient hosts. J Exp Med 197: 1405-1416.
73. Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE. 2012. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS ONE 7: e35106.
74. Xue J, Chen X, Selby D, Hung CY, Yu JJ, Cole GT. 2009. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77: 3196-3208.
75. Yuan R, Casadevall A, Spira G, Scharff MD. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 154: 1810-1816.